The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prognostic factors for chemotherapy-related toxicity in primary central nervous system lymphoma (PCNSL) treated with high-dose methotrexate (HDMTX) with or without ifosfamide: Results from a German phase III trial (G-PCNSL-SG-1).
P. Martus
No relevant relationships to disclose
K. Jahnke
No relevant relationships to disclose
A. Korfel
No relevant relationships to disclose
T. Rose
No relevant relationships to disclose
L. Fischer
No relevant relationships to disclose
R. Moehle
No relevant relationships to disclose
H. A. Klasen
No relevant relationships to disclose
M. Rauch
No relevant relationships to disclose
A. Roeth
No relevant relationships to disclose
B. Hertenstein
No relevant relationships to disclose
T. Fischer
No relevant relationships to disclose
T. Hundsberger
No relevant relationships to disclose
H. Mergenthaler
No relevant relationships to disclose
M. Leithäuser
No relevant relationships to disclose
T. Birnbaum
No relevant relationships to disclose
U. Herrlinger
No relevant relationships to disclose
J. Schubert
No relevant relationships to disclose
J. Birkmann
No relevant relationships to disclose
M. Weller
No relevant relationships to disclose
E. Thiel
No relevant relationships to disclose